Adrian Towse

Office of Health Economics

MA, MPhil

12 Whitehall

London, SW1A 2DY

United Kingdom

http://www.ohe.org

SCHOLARLY PAPERS

18

DOWNLOADS
Rank 35,049

SSRN RANKINGS

Top 35,049

in Total Papers Downloads

1,658

SSRN CITATIONS
Rank 26,352

SSRN RANKINGS

Top 26,352

in Total Papers Citations

11

CROSSREF CITATIONS

24

Scholarly Papers (18)

1.

Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and Patents

Number of pages: 35 Posted: 16 Jul 2003
Patricia M. Danzon and Adrian Towse
University of Pennsylvania - The Wharton School and Office of Health Economics
Downloads 860 (33,838)
Citation 29

Abstract:

Loading...

differential pricing, pharmaceuticals, developing countries, parallel trade, Global Fund

2.

New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options

Number of pages: 52 Posted: 25 Aug 2015
Priya Sharma and Adrian Towse
Office of Health Economics and Office of Health Economics
Downloads 172 (211,078)
Citation 13

Abstract:

Loading...

3.

Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?

Number of pages: 7 Posted: 25 Aug 2015
Martina Garau, Adrian Towse and Patricia M. Danzon
Office of Health Economics, Office of Health Economics and University of Pennsylvania - The Wharton School
Downloads 113 (293,492)
Citation 2

Abstract:

Loading...

4.

Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold

Number of pages: 71 Posted: 25 Aug 2015
Office of Health Economics, Office of Health Economics, Office of Health Economics and RAND Europe
Downloads 107 (304,931)
Citation 11

Abstract:

Loading...

5.

What is the Role of HTA for Biosimilars?

Number of pages: 48 Posted: 25 Aug 2015
Jorge Mestre-Ferrandiz and Adrian Towse
Office of Health Economics and Office of Health Economics
Downloads 89 (343,549)
Citation 2

Abstract:

Loading...

6.

The Market for Biosimilars: Evolution and Policy Options

OHE Briefing, No. 45, October 2008
Number of pages: 24 Posted: 27 Aug 2015
Merck & Co., Inc. - Merck Serono Company, Office of Health Economics and Office of Health Economics
Downloads 57 (438,212)

Abstract:

Loading...

7.

Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context

NBER Working Paper No. w18593
Number of pages: 23 Posted: 07 Dec 2012 Last Revised: 22 Apr 2021
University of Pennsylvania - The Wharton School, Office of Health Economics and Office of Health Economics
Downloads 50 (464,610)

Abstract:

Loading...

8.

Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches

OHE Research Paper 11/04
Number of pages: 32 Posted: 19 Aug 2015
Jon Sussex, Adrian Towse and Nancy Devlin
RAND Europe, Office of Health Economics and Office of Health Economics
Downloads 30 (558,402)
Citation 1

Abstract:

Loading...

9.

International Decision Support Initiative: Mapping of Priority-Setting in Health for 17 Low and Middle Countries Across Asia, Latin America and Africa

Number of pages: 123 Posted: 25 Aug 2015
Office of Health Economics, NICE International, Office of Health Economics and NICE International
Downloads 29 (570,109)
Citation 1

Abstract:

Loading...

10.

Comparative and Relative Effectiveness: A Challenge for Health Systems, Regulators, or Pharmaceutical Companies?

Number of pages: 13 Posted: 23 Aug 2015
Adrian Towse
Office of Health Economics
Downloads 28 (570,109)

Abstract:

Loading...

11.

Incentives for R&D for New Antimicrobial Drugs

OHE Research Paper 11/02
Number of pages: 20 Posted: 19 Aug 2015
Adrian Towse and Priya Sharma
Office of Health Economics and Office of Health Economics
Downloads 26 (582,516)

Abstract:

Loading...

12.

Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

OHE Research Paper 12/03
Number of pages: 27 Posted: 19 Aug 2015
Office of Health Economics, Office of Health Economics, University of Washington, University of Washington and Novartis Institutes for Biomedical Research - Novartis Pharma AG
Downloads 23 (601,976)
Citation 3

Abstract:

Loading...

13.

Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement

NBER Working Paper No. w17174
Number of pages: 33 Posted: 05 Jul 2011 Last Revised: 06 Jun 2021
University of Pennsylvania - The Wharton School, University of Pennsylvania - The Wharton School and Office of Health Economics
Downloads 22 (608,772)
Citation 2

Abstract:

Loading...

14.

Using QALYs in Cancer: A Review of the Methdological Limitations

Number of pages: 28 Posted: 22 Aug 2015
Office of Health Economics, Office of Health Economics, University of York, Independent, Office of Health Economics and University of York - Centre for Health Economics
Downloads 17 (643,106)

Abstract:

Loading...

15.

The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?

Number of pages: 14 Posted: 25 Aug 2015
Adrian Towse, Louis Garrison and Ruth Puig-Peiro
Office of Health Economics, University of Washington and Office of Health Economics
Downloads 13 (672,402)
Citation 2

Abstract:

Loading...

16.

Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds. Notes on a Conference in Honour of Bernie O’Brien.

OHE Briefing, No. 42, October 2006
Number of pages: 16 Posted: 27 Aug 2015
Adrian Towse and Martin Buxton
Office of Health Economics and Brunel University London - Health Economics Research Group (HERG)
Downloads 11 (687,474)

Abstract:

Loading...

17.

Is the Link between Health and Wealth Considered in Decision Making? Results from a Qualitative Study

Number of pages: 20 Posted: 16 Aug 2015
Office of Health Economics, Office of Health Economics, United States Agency for International Development (USAID) and Office of Health Economics
Downloads 11 (687,474)

Abstract:

Loading...

18.

Modelling the R&D Process for Global Diseases Driven By Public-Private Partnersips (PPPs)

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 07 Jul 2007
University of Nottingham, Office of Health Economics, Office of Health Economics, Office of Health Economics, University of Oxford - Health Economics Research Centre (HERC) and Office of Health Economics

Abstract:

Loading...

Markov model, R&D process, global diseases

Other Papers (1)

Total Downloads: 0
1.

Donor Investment Choices in Developing Countries: A Methodology and Some Illustrative Results Based on Public-Private Partnerships for Product Development (PD PPPs)

iHEA 2007 6th World Congress: Explorations in Health Economics Paper
Posted: 09 Jun 2007
University of Oxford - Health Economics Research Centre (HERC), University of Nottingham, Office of Health Economics, Office of Health Economics and Office of Health Economics

Abstract:

Loading...

Cost-effectiveness frontiers, R&D process, global diseases, Product Development Public Private Partnerships